Drugs & Aging

, Volume 31, Issue 5, pp 339–347

Chronic Hepatitis C in the Aged: Much Ado About Nothing or Nothing to Do?

Therapy in Practice


Hepatitis C is a common infection worldwide. It is a major cause of cirrhosis and its complications, including hepatocellular carcinoma and liver transplantation. Treatment of hepatitis C has dramatically improved since its discovery. Current treatment includes pegylated interferon and ribavirin, and the addition of the protease inhibitors telaprevir, boceprevir, or simeprevir, or the polymerase inhibitor sofosbuvir. The rate of sustained viral response, considered a cure, now approaches 80 %. These treatments are complex, with multiple morbidities and drug interactions. The majority of patients with chronic hepatitis C are from the birth cohort of the ‘baby boomer’ years (1945–1965) with the oldest already 68 years old. In spite of this, most hepatitis C patients in clinical trials have been much younger and this is still the case in the ongoing studies. Thus, the group of patients most likely to require treatment in the future will have decisions made with a relative lack of evidence-based medicine. It is the purpose of this article to review the epidemiology, clinical manifestations, and treatment of hepatitis C with the data available in the aged population.


  1. 1.
    Topinková E, Baeyens JP, Michel J-P, Lang P-O. Evidence-based strategies for the optimization of pharmacotherapy in older people. Drugs Aging. 2012;1(29):477–94.CrossRefGoogle Scholar
  2. 2.
    Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Smith BD, Morgan RL, Beckett GA, et al. Hepatitis C virus testing of persons born during 1945–1965: recommendations from the centers for disease control and prevention. Ann Intern Med. 2012;157:817–22.PubMedCrossRefGoogle Scholar
  4. 4.
    Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int. 2009;29(suppl 2):13–25.PubMedCrossRefGoogle Scholar
  5. 5.
    Rosen H. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364:2429–38.PubMedCrossRefGoogle Scholar
  6. 6.
    Crome P, Natarajan I. The National Service Framework for Older People: England’s approach to ending age discrimination in services and therapeutics. Drugs Aging. 2004;21:499–510.PubMedCrossRefGoogle Scholar
  7. 7.
    Terrault NA, Dodge JL, Murphy EL, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013;57:881–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Ohto H, Terazawa S, Sasaki N, Sasaki N, Hino K, Ishiwata C, et al. Transmission of hepatitis C virus from mothers to infants. The vertical transmission of hepatitis C virus collaborative study group. N Engl J Med. 1994;330:744–50.PubMedCrossRefGoogle Scholar
  9. 9.
    Geerlings W, Tufveson G, Ehrich JH, et al. Report on management of renal failure in Europe XXIII. Nephrol Dial Transplant. 1994;9(suppl 1):6–25.PubMedGoogle Scholar
  10. 10.
    Alter MJ. HCV routes of transmission: what goes around comes around. Semin Liver Dis. 2011;31:340–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Chien NT, Dundoo G, Horani MH, et al. Seroprevalence of viral hepatitis in an older nursing home population. J Am Geriatr Soc. 1999;47:1110–3.PubMedGoogle Scholar
  12. 12.
    Monica F, Lirussi F, Pregun I, et al. Hepatitis C virus infection in a resident elderly population: a 10-year follow-up study. Dig Liver Dis. 2006;38:336–40.PubMedCrossRefGoogle Scholar
  13. 13.
    Heydtmann M, Adams DH. Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology. 2009;49:676–88.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    González-Peralta RP, Qian K, She JY, et al. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. J Med Virol. 1996;49:242–7.PubMedCrossRefGoogle Scholar
  15. 15.
    El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;18(139):817–23.CrossRefGoogle Scholar
  16. 16.
    Wiese M, Grüngreiff K, Güthoff W, et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany—a 25-year multicenter study. J Hepatol. 2005;43:590–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001;34:730–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Ryder SD, Irving WL, Jones DA, et al. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut. 2004;53:451–5.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Merican I, Sherlock S, McIntyre N, Dusheiko GM. Clinical, biochemical and histological features in 102 patients with chronic hepatitis C virus infection. Q J Med. 1993;86:119–25.PubMedGoogle Scholar
  20. 20.
    McAndrews MP, Farcnik K, Carlen P, et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology. 2005;41:801–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth cohort screening for hepatitis C antibody in US primary care settings. Ann Intern Med. 2012;156:263–70.PubMedCrossRefGoogle Scholar
  22. 22.
    Gretch DR. Diagnostic tests for hepatitis C. Hepatology. 1997;26(3 Suppl 1):43S–7S.PubMedCrossRefGoogle Scholar
  23. 23.
    Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology. 2007;46:22–31.PubMedCrossRefGoogle Scholar
  24. 24.
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–93.PubMedCrossRefGoogle Scholar
  25. 25.
    Castera L, Bedossa P. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy? Liver Int. 2011;31(Suppl 1):13–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Jacobson IM, Pawlotsky J-M, Afdhal NH, et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat. 2012;19:1–26.PubMedCrossRefGoogle Scholar
  27. 27.
    Bruno S, Battezzati PM, Bellati G, et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol. 2001;34:748–55.PubMedCrossRefGoogle Scholar
  28. 28.
    Bresci G, Del Corso L, Romanelli AM, et al. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis. J Am Geriatr Soc. 1993;41:857–62.PubMedGoogle Scholar
  29. 29.
    Horiike N, Masumoto T, Nakanishi K, et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol. 1995;10:246–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Van Thiel DH, Friedlander L, Caraceni P, et al. Treatment of hepatitis C virus in elderly persons with interferon alpha. J Gerontol A Biol Sci Med Sci. 1995;50:M330–3.PubMedCrossRefGoogle Scholar
  31. 31.
    Alessi N, Freni MA, Spadaro A, et al. Efficacy of interferon treatment (IFN) in elderly patients with chronic hepatitis C. Infez Med. 2003;11:208–12.PubMedGoogle Scholar
  32. 32.
    Koyama R, Arase Y, Ikeda K, et al. Efficacy of interferon therapy in elderly patients with chronic hepatitis C. Intervirology. 2006;49:121–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Honda T, Katano Y, Urano F, et al. Efficacy of ribavirin plus interferon-alpha in patients aged ≥60 years with chronic hepatitis C. J Gastroenterol Hepatol. 2007;22:989–95.PubMedCrossRefGoogle Scholar
  34. 34.
    Imai Y, Kasahara A, Tanaka H, et al. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. J Gastroenterol. 2004;39:1069–77.PubMedCrossRefGoogle Scholar
  35. 35.
    Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology. 2007;50:16–23.PubMedCrossRefGoogle Scholar
  36. 36.
    Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology. 2006;43:54–63.PubMedCrossRefGoogle Scholar
  37. 37.
    Tsui JI, Currie S, Shen H, et al. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 study. Dig Dis Sci. 2008;53:809–14.PubMedCrossRefGoogle Scholar
  38. 38.
    Floreani A, Minola E, Carderi I, et al. Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C? J Am Geriatr Soc. 2006;54:549–50.PubMedCrossRefGoogle Scholar
  39. 39.
    Antonucci G, Longo MA, Angeletti C, et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol. 2007;102:1383–91.PubMedCrossRefGoogle Scholar
  40. 40.
    Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol. 2006;101:1260–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Nudo CG, Wong P, Hilzenrat N, Deschênes M. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol. 2006;20:589–92.PubMedCentralPubMedGoogle Scholar
  42. 42.
    Kainuma M, Furusyo N, Kajiwara E, et al. Pegylated interferon α-2b plus rubavarin for patients with chronic hepatitis C. World J Gastroenterol. 2010;16:4400–9.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Gramenzi A, Conti F, Cammà C, et al. Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver. Dig Liver Dis. 2012;44:674–80.PubMedCrossRefGoogle Scholar
  44. 44.
    Hu C-C, Lin C-L, Kuo Y-L, et al. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C. Aliment Pharmacol Ther. 2013;37:81–90.PubMedCrossRefGoogle Scholar
  45. 45.
    Frei P, Leucht AK, Kofmehl R et al. Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis c virus patients. Liver Int 2013. doi:10.1111/liv.12279.
  46. 46.
    Yee HS, Chang MF, Pocha C, et al. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans affairs Hepatitis C resource center program and the National hepatitis C Program office. Am J Gastroenterol. 2012;107:669–89.PubMedCrossRefGoogle Scholar
  47. 47.
    Furusyo N, Ogawa E, Nakamuta M, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol. 2013;59:205–12.PubMedCrossRefGoogle Scholar
  48. 48.
    Moreno C, Wedemeyer H, Fernandez I, et al. Efficacy and safety results of treatment of patients over 65 years old with genotype 1 hepatitis C with severe fibrosis or compensated cirrhosis: the International Telaprevir Early Access Program. Hepatology. 2013;58(4(suppl)):186 A (Abstract 1911).Google Scholar
  49. 49.
    Hezode C, Fontaine H, Dufour C, et al. Efficacy and safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavarin in cirrhotics according to the age. Data from the CUPIC cohort (ANRS C020). Hepatology. 2013;58(4(suppl)):181A (Abstract 1845).Google Scholar
  50. 50.
    Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–87.PubMedCrossRefGoogle Scholar
  51. 51.
    Jacobson IM, Dore GJ, Foster GR et al. Simeprevir (TMC435) with peginterferon/ribavarin for chronic HCV genotype 1 infection in treatment-naive patients: results from QUEST-1, a phase III trial. Program and abstracts of the 48th Annual Meeting of the European Association for the Study of the Liver. April 24–28, 2013. Amsterdam, The Netherlands Abstract 1425.Google Scholar
  52. 52.
    Manns M, Marcellin P, Poordad F, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive patients: results from QUEST-2, a phase III trial. Presented at the 48th annual meeting of the European Association for the Study of the Liver, Amsterdam, The Netherlands, April 24–28, 2013. Abstract 1413.Google Scholar
  53. 53.
    McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;6:361580–93.Google Scholar
  54. 54.
    Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Liver Int. 2009;29(Suppl 1):15–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care. 2004;27:2444–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Kagansky N, Levy S, Keter D, et al. Non-alcoholic fatty liver disease—a common and benign finding in octogenarian patients. Liver Int. 2004;24:588–94.PubMedCrossRefGoogle Scholar
  57. 57.
    Abu-Mouch S, Fireman Z, Jarchovsky J, et al. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol. 2011;21(17):5184–90.CrossRefGoogle Scholar
  58. 58.
    Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World J Gastroenterol. 2012;18:800–5.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Houston DK, Tooze JA, Davis CC, et al. Serum 25-hydroxyvitamin D and physical function in older adults: the Cardiovascular Health Study All Stars. J Am Geriatr Soc. 2011;59:1793–801.PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Rocco A, Compare D, Coccoli P, et al. Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. Gut. 2013;62:766–73.PubMedCrossRefGoogle Scholar
  61. 61.
    Burger D, Back D, Buggisch P et al. Clinical management of drug–drug interactions in HCV therapy: Challenges and solutions. J Hepatol. doi:10.1016/j.jhep.2012.10.027.
  62. 62.
    The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;2012(60):616–31.CrossRefGoogle Scholar
  63. 63.
    Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–21.PubMedCrossRefGoogle Scholar
  64. 64.
    American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians. J Am Geriatr Soc. 2012;60(10):E1–25.CrossRefGoogle Scholar
  65. 65.
    Welch HG, Albertsen PC, Nease RF, et al. Estimating treatment benefits for the elderly:the effect of competing risks. Ann Intern Med. 1996;124:577–84.PubMedCrossRefGoogle Scholar
  66. 66.
    United States Life Tables 2009, National Vital Statistics Reports 2014;62(7).Google Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Department of Internal Medicine C, Kaplan Medical CenterAffiliated with the Hebrew University of JerusalemRehovotIsrael
  2. 2.Gastroenterology Institute, Kaplan Medical CenterAffiliated with the Hebrew University of JerusalemRehovotIsrael
  3. 3.Geriatrics Department, Kaplan Medical CenterAffiliated with the Hebrew University of JerusalemRehovotIsrael

Personalised recommendations